Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity

Clinica Chimica Acta

Volumn 252, Issue 1, 1996, Pages 1-9

  Tateishi, Tomonori ^a   Nakura, Hironori ^a   Watanabe, Minoru ^a   Tanaka, Masami ^a   Kumai, Toshio ^a   Kobayashi, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Cytosolic protein; Dihydropyrimide dehydrogenase; Incubation time; Substrate concentration

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ANIMAL TISSUE; CONTROLLED STUDY; ENZYME ASSAY; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT SURVEY; TECHNIQUE;

ANIMALIA;

EID: 0030586973     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-8981(96)06315-2     Document Type: Article

References (13)

1. [1] Köhne-Wömpner C-H, Schmoll H-J, Harstrick A, Rustum YM. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol 1992;19(S3):105-125.
2. [2] Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
3. [3] Rustum YM, Cao S, Spector T. 5-Ethynyluracil (776C85) is a potent modulator of the therapeutic activity of 5-fluorouracil. Proc Am Assoc Cancer Res 1993;34:283.
4. [4] Baccanari DP, Davis ST, Knick VC et al. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993;90:11064-11068.
5. [5] Tuchman M, Stoeckeler JS, Kiand DT, O'Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985;313:245-249.
6. [6] Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81:47-51.
7. [7] Naguib FNM, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985;45:5405-5412.
8. [8] Tuchman M, Ramnaraine MLR, O'Dea RF. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res 1985;45:5553-5556.
9. [9] Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-5438.
10. [10] Lu Z, Zhang R, Diasio RB. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochem Pharmacol 1993;46:945-952.
11. [11] Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
12. [12] Sommadossi J-P, Gewirtz DA, Diasio RB, Aubert C, Cano J-P, Goldman ID. Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 1982;257:8171-8176.
13. [13] Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-2253.